Financings in Brief: Applied Immune Sciences
This article was originally published in The Gray Sheet
Executive Summary
Applied Immune Sciences: Receives $21.5 mil. in cash from the sale of newly issued common stock to Rhone-Poulenc Rorer. The sale was made in conjunction with AIS' meeting the second of three funding milestones under a 1993 strategic alliance between the two companies ("The Gray Sheet" June 7, 1993, p. 10). AIS reached the milestone by gaining FDA approval for a clinical trial investigating "a new approach to adjunctive leukemia therapy that is based on research indicating that infused T cell depleted donor peripheral blood improves the immune response of the leukemia patient after allogeneic bone marrow transplantation." AIS received a $21 mil. investment from RPR in January following approval of an investigational device exemption for the AIS CELLector device for purging T and B cells from allogeneic bone marrow ("The Gray Sheet" Jan. 23, 1995). The CELLector will be used in the newly approved trial as well...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.